SecBot SecBot
6-K ·Filed Jun 29, 2026

GSK

GSK plc
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001654954-26-006273
Notable filing: 6-K
Actionable Insight • Neutral

The completion of the £2 billion buyback removes a known capital return catalyst. Monitor GSK's next capital allocation announcement for any new buyback or dividend policy. No immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$52.81
T+0 close · Jun 29, 2026 · via day close
Latest settled
−3.96%
T+60 · $50.72
Vs SPY
−8.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $52.81entry
  2. T+1 · 5mo ago −0.74%α −1.52% · $52.42
  3. T+5 · 4mo ago +0.53%α −0.86% · $53.09
  4. T+20 · 4mo ago −2.76%α −2.49% · $51.35
  5. T+60 · 8w ago −3.96%α −8.33% · $50.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK completed its £2 billion share buyback program, purchasing 123,939,156 ordinary shares since February 24, 2025. The final tranche of 1,054,653 shares was bought between June 22-26, 2026, at an average price of approximately 1,953.54 GBp per share. This is a routine capital return milestone with no new financial data or strategic changes.

Key Facts

  • GSK completed its £2 billion buyback program announced on February 24, 2025.
  • Since February 24, 2025, GSK purchased 123,939,156 ordinary shares for aggregate consideration of just under £2 billion.
  • The final week (June 22-26, 2026) saw purchases of 1,054,653 shares at volume-weighted average prices between 1,919.89 GBp and 1,967.46 GBp.
  • Following purchases, GSK holds 270,881,064 shares in treasury and has 4,045,395,364 shares in issue (excluding treasury).
  • Treasury shares represent 6.70% of total voting rights.

Financial Impact

£2 billion total buyback completed; no new financial data or guidance provided.

share counttreasury shares

Risk Factors

  • No new buyback program announced; capital return to shareholders may pause.
  • Treasury shares at 6.70% could be reissued for acquisitions or employee compensation, potentially diluting future EPS.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006273
Document: 0001654954-26-006273-index-headers.html0001654954-26-006273
Document: 0001654954-26-006273-index.html0001654954-26-006273
Document: 0001654954-26-006273.txt0001654954-26-006273

US Market Status

Market Closed · Opens Wed (10h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026